Molecular genetics of mitral valve prolapse

Current Opinion in Cardiology

Volumn 22, Issue 3, 2007, Pages 171-175

  Levine, Robert A ^a   Slaugenhaupt, Susan A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Filamin A; Genetics; Growth factor; Mitral regurgitation; Mitral valve prolapse

Indexed keywords

COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FIBRILLIN 1; FIBROBLAST GROWTH FACTOR 4; FILAMIN A; LOSARTAN; MATRIX METALLOPROTEINASE; SMAD6 PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR SOX4; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA;

AORTA ANEURYSM; AORTA VALVE; ARTICLE; CHROMOSOME 11; CHROMOSOME 13; CHROMOSOME 16; ECHOCARDIOGRAPHY; EHLERS DANLOS SYNDROME; GENE MUTATION; GENETIC DISORDER; HEART VALVE; HUMAN; LOEYS DIETZ SYNDROME; MARFAN SYNDROME; MITRAL VALVE PROLAPSE; MITRAL VALVE REGURGITATION; MOLECULAR GENETICS; MOUSE STRAIN; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL;

ANIMALS; CONTRACTILE PROTEINS; DISEASE PROGRESSION; GENETIC RESEARCH; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROFILAMENT PROTEINS; MITRAL VALVE PROLAPSE; MOLECULAR BIOLOGY; PHENOTYPE; RISK FACTORS;

EID: 34247142706     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3280f3bfcd     Document Type: Article

References (56)

1. Freed LA, Benjamin EJ, Levy D, et al. Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study. J Am Coll Cardiol 2002; 40:1298-1304.
2. Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999; 341:1-7.
3. Tamura K, Fukuda Y, Ishizaki M, et al. Abnormalities in elastic fibers and other connective-tissue components of floppy mitral valve. Am Heart J 1995; 129:1149-1158.
4. Rabkin E, Aikawa M, Stone JR, et al. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 2001; 104:2525-2532.
5. Devereux RB, Kramer-Fox R, Shear MK, et al. Diagnosis and classification of severity of mitral valve prolapse: methodologic, biologic, and prognostic considerations. Am Heart J 1987; 113:1265-1280.
6. Braunwald E. Heart disease: A textbook of cardiovascular medicine. W.B. Saunders Company 1992.
7. Avierinos JF, Gersh BJ, Melton LJ 3rd, et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation 2002; 106:1355-1361.
8. Ling LH, Enriquez-Sarano M, Seward JB, et al. Clinical outcome of mitral regurgitation due to flail leaflet. N Engl J Med 1996; 335:1417-1423.
9. Waller BF, Morrow AG, Maron BJ, et al. Etiology of clinically isolated, severe, chronic, pure mitral regurgitation: analysis of 97 patients over 30 years of age having mitral valve replacement. Am Heart J 1982; 104:276-288.
10. Warth DC, King ME, Cohen JM, et al. Prevalence of mitral valve prolapse in normal children. J Am Coll Cardiol 1985; 5:1173-1177.
11. Levine RA, Triulzi MO, Harrigan P, Weyman AE. The relationship of mitral annular shape to the diagnosis of mitral valve prolapse. Circulation 1987; 75:756-767.
12. Levine RA, Stathogiannis E, Newell JB, et al. Reconsideration of echocardiographic standards for mitral valve prolapse: lack of association between leaflet displacement isolated to the apical four chamber view and independent echocardiographic evidence of abnormality. J Am Coll Cardiol 1988; 11:1010-1019.
13. Levine RA, Handschumacher MD, Sanfilippo AJ, et al. Three-dimensional echocardiographic reconstruction of the mitral valve, with implications for the diagnosis of mitral valve prolapse. Circulation 1989; 80:589-598.
14. Perloff JK, Child JS. Mitral valve prolapse: evolution and refinement of diagnostic techniques. Circulation 1989; 80:710-711.
15. Lucas RV Jr, Edwards JE. The floppy mitral valve. Curr Probl Cardiol 1982; 7:1-48.
16. Grande-Allen KJ, Griffin BP, Calabro A, et al. Myxomatous mitral valve chordae. II: Selective elevation of glycosaminoglycan content. J Heart Valve Dis 2001; 10:325-332; discussion 332-333.
17. Brown CB, Boyer AS, Runyan RB, Barnett JV. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science 1999; 283:2080-2082.
18. Akiyama H, Chaboissier MC, Behringer RR, et al. Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa. Proc Natl Acad Sci U S A 2004; 101:6502-6507.
19. Srivastava D, Olson EN. A genetic blueprint for cardiac development. Nature 2000; 407:221-226.
20. Ranger AM, Grusby MJ, Hodge MR, et al. The transcription factor NF-ATc is essential for cardiac valve formation. Nature 1998; 392:186-190.
21. de la Pompa JL, Timmerman LA, Takimoto H, et al. Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature 1998; 392:182-186.
22. Hurlstone AF, Haramis AP, Wienholds E, et al. The Wnt/beta-catenin pathway regulates cardiac valve formation. Nature 2003; 425:633-637.
23. Sugi Y, Ito N, Szebenyi G, et al. Fibroblast growth factor (FGF)-4 can induce proliferation of cardiac cushion mesenchymal cells during early valve leaflet formation. Dev Biol 2003; 258:252-263.
24. Schilham MW, Oosterwegel MA, Moerer P, et al. Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4. Nature 1996; 380:711-714.
25. Galvin KM, Donovan MJ, Lynch CA, et al. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet 2000; 24:171-174.
26. Rabkin-Aikawa E, Aikawa M, Farber M, et al. Clinical pulmonary auto-graft valves: pathologic evidence of adaptive remodeling in the aortic site. J Thorac Cardiovasc Surg 2004; 128:552-561.
27. Aikawa E, Whittaker P, Farber M, et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation 2006; 113:1344-1352. Demonstration of valve plasticity.
28. Paruchuri S, Yang J-H, Aikawa E, et al. Human pulmonary valve progenitor cells exhibit endothelial/mesenchymal plasticity in response to vascular endothelial growth factor-A and transforming growth factor-b2. Circ Res 2006; 99:861-869. Demonstration of valve plasticity.
29. Grande-Allen KJ, Griffin BP, Ratliff NB, et al. Glycosamino-glycan profiles of myxomatous mitral leaflets and chordae parallel the severity of mechanical alterations. J Amer Coll Cardiol 2003; 42:271-277.
30. Armstrong EJ, Bischoff J. Heart valve development: endothelial cell signaling and differentiation. Circ Res 2004; 95:459-470.
31. Ng CM, Cheng A, Myers LA, et al. TGF-β-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004; 114:1586-1592.
32. Sugi Y, Yamamura H, Okagawa H, Markwald RR. Bone morphogenetic protein-2 can mediate myocardial regulation of atrioventricular cushion mesenchymal cell formation in mice. Dev Biol 2004; 269:505-518.
33. Devereux RB, Brown WT, Kramer-Fox R, Sachs I. Inheritance of mitral valve prolapse: effect of age and sex on gene expression. Ann Intern Med 1982; 97:826-832.
34. Weiss AN, Mimbs JW, Ludbrook PA, Sobel BE. Echocardiographic detection of mitral valve prolapse: exclusion of false positive diagnosis and determination of inheritance. Circulation 1975; 52:1091-1096.
35. Strahan NV, Murphy EA, Fortuin NJ, et al. Inheritance of the mitral valve prolapse syndrome: discussion of a three-dimensional penetrance model. Am J Med 1983; 74:967-972.
36. Zuppiroli A, Roman MJ, O'Grady M, Devereux RB. A family study of anterior mitral leaflet thickness and mitral valve prolapse. Am J Cardiol 1998; 82:823-826; A810.
37. Malcolm AD. Mitral valve prolapse associated with other disorders: casual coincidence, common link, or fundamental genetic disturbance? Br Heart J 1985; 53:353-362.
38. Glesby MJ, Pyeritz RE. Association of mitral valve prolapse and systemic abnormalities of connective tissue: a phenotypic continuum. JAMA 1989; 262:523-528.
39. Milewicz DM. Molecular genetics of Marfan syndrome and Ehlers-Danlos type IV. Curr Opin Cardiol 1998; 13:198-204.
40. Rubegni P, Mondillo S, De Aloe G, et al. Mitral valve prolapse in healthy relatives of patients with familial pseudoxanthoma elasticum. Am J Cardiol 2000; 85:1268-1271.
41. Struk B, Neldner KH, Rao VS, et al. Mapping of both autosomal recessive and dominant variants of pseudoxanthoma elasticum to chromosome 16p13.1. Hum Mol Genet 1997; 6:1823-1828.
42. Malfait F, De Paepe S. Molecular genetics in classic Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet 2005; 139:17-23.
43. Roman MJ, Devereux RB, Kramer-Fox R, Spitzer MC. Comparison of cardiovascular and skeletal features of primary mitral valve prolapse and Marfan syndrome. Am J Cardiol 1989; 63:317-321.
44. Henney AM, Tsipouras P, Schwartz RC, et al. Genetic evidence that mutations in the COL1A1, COL1A2, COL3A1, or COL5A2 collagen genes are not responsible for mitral valve prolapse. Br Heart J 1989; 61:292-299.
45. Wordsworth P, Ogilvie D, Akhras F, et al. Genetic segregation analysis of familial mitral valve prolapse shows no linkage to fibrillar collagen genes. Br Heart J 1989; 61:300-306.
46. Disse S, Abergel E, Berrebi A, et al. Mapping of a first locus for autosomal dominant myxomatous mitral-valve prolapse to chromosome 16p11.2-p12.1. Am J Hum Genet 1999; 65:1242-1251.
47. Freed LA, Acierno JS Jr, Dai D, et al. A locus for autosomal dominant mitral valve prolapse on chromosome 11p15.4. Am J Hum Genet 2003; 72:1551-1559.
48. Nesta F, Leyne M, Yosefy C, et al. New locus for autosomal dominant mitral valve prolapse on chromosome 13: clinical insights from genetic studies. Circulation 2005; 112:2022-2030. New linkage site for familial MVP and description of a prodromal form with the same haplotype.
49. Kyndt F, Schott JJ, Trochu JN, et al. Mapping of X-linked myxomatous valvular dystrophy to chromosome Xq28. Am J Hum Genet 1998; 62:627-632.
50. Kyndt F, Gueffet JP, Probst V, et al. Mutations in the gene encoding filamin Aas a cause for familial cardiac valvular dystrophy. Circulation 2007; 115:40-49. First gene found for valve dystrophy of mitral and aortic valves not related to known connective tissue syndromes.
51. Solomon SD, Jarcho JA, McKenna W, et al. Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease. J Clin Invest 1990; 86:993-999.
52. Maron BJ, Moller JH, Seidman CE, et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome: a statement for healthcare professionals from the Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Basic Science, American Heart Association. Circulation 1998; 98:1460-1471.
53. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005; 37:275-281. New syndrome confirming role of growth signal overactivity.
54. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312:117-121. Translational benefit from recognition of role of growth signal overactivity in Marfan syndrome.
55. Charitakis K, Basson CT. Degenerating heart valves: fill them up with filamin? Circulation 2007; 115:2-4. Editorial on first gene finding for nonsyndromic mitral and aortic valve dystrophy.
56. Oyama MA, Chittur SV. Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease. Am J Vet Res 2006; 67:1307-1318.